Amended and Restated

Condensed Consolidated Interim Financial Statements

For the Three Months Ended December 31, 2017

(Unaudited)

(Expressed in Canadian dollars)

NOTICE TO READER

In accordance with National Instrument 51-102 released by the Canadian Securities Administrators, the Company must disclose if an auditor has not performed a review of the interim financial statements.

The accompanying unaudited restated consolidated interim financial statements have been prepared by and are the responsibility of the Company's management.

These unaudited restated consolidated interim financial statements have not been reviewed on behalf of the shareholders by the independent external auditors of the Company.

Condensed Consolidated Interim Statements of Financial Position – Amended and Restated (Unaudited)

(Expressed in Canadian dollars)

		December 31, 3 2017 \$	September 30, 2017 \$
		(Restated) (Note 16)	(Restated) (Note 16)
Assets			
Current Assets			
Cash and cash equivalents Sales tax receivable Prepayments		54,350 141,535 16,963	19,475 100,747 -
		212,848	120,222
Plant and equipment (Note 5) Intangible asset (Note 4)		288,699 26,469	301,863 30,250
		528,016	452,335
Liabilities and Shareholders' Equity			
Current Liabilities			
Cheques in excess of funds available Accounts payable and accrued liabilities (Note 6) Advance from Investissement Québec (Note 7) Due to related parties (Note 9) Note payable (Note 8)		433,044 148,500 177,308	5,096 214,468 148,500 42,076 120,000
		758,852	530,140
Shareholders' Equity			
Share capital (Note 10) Reserves (Note 10) Subscriptions received in advance (Note 10)		7,796,040 8,373,729	6,733,442 8,212,838 409,598
Deficit		(16,400,605)	(15,433,683)
		(230,836)	(77,805)
		528,016	452,335
Nature of operations and going concern (Note 1) Commitments (Note 13) Subsequent events (Note 15)			
Approved by the Board of Directors on August 10,	2018:		
"Nelson Skalbania"	"Gillian Holcroft"		
Director	Director		

(The accompanying notes are an integral part of these condensed consolidated interim financial statements)

Condensed Consolidated Interim Statements of Loss and Comprehensive Loss – Amended and Restated (Unaudited)

(Expressed in Canadian dollars)

	Three months ended December 31, 2017 \$	Three months ended December 31, 2016 \$
	(Restated) (Note 16)	
Administrative Expenses	(11010-10)	
Amortization (Notes 4 and 5)	18,201	-
Office and administration	31,447	17,155
Professional and consulting fees	151,335	132,537
Investor communication	140,499	51,904
Research	255,398	182,247
Travel	33,483	19,476
Trust and filing fees	4,260	4,648
	(634,623)	(407,967)
Other Item		4
Interest expense	(397)	(7,617)
Loss on settlement of debts (Notes 8 and 9)	(331,902)	
Net loss for the period	(966,922)	(415,584)
Other comprehensive income		
Foreign currency translation adjustment	14,660	10,133
Comprehensive loss for the period	(952,262)	(405,451)
Income (loss) per share, basic and diluted	(0.02)	(0.01)
Weighted average shares outstanding	43,450,221	32,356,170

Condensed Consolidated Interim Statement of Changes in Equity – Amended and Restated (Unaudited) (Expressed in Canadian dollars)

	Share	Capital		Reser	ve				
	Common Shares	Amount \$	Warrant \$	Loan \$	Option \$	Translation gain (loss)	Subscriptions received in advance \$	Deficit Total \$ \$	
September 30, 2016	34,335,283	5,403,250	1,017,000	2,664,963	3,741,520	6,002	-	(12,605,091)	227,644
Foreign exchange adjustment Share issuance – warrant exercise	-	-	-	-	-	10,133	-	-	10,133
(Note 10b) Net loss	45,000 -	27,000	-	-	-	-	-	(415,584)	27,000 (415,584)
December 31, 2016	34,380,283	5,430,250	1,017,000	2,664,963	3,741,520	16,135	-	(13,020,675)	(150,807)
September 30, 2017 (Restated)	40,151,343	6,733,442	1,035,573	2,664,963	4,498,512	13,790	409,598	(15,433,683)	(77,805)
Foreign exchange adjustment Unit issuance for cash (Note 10b)	2,047,990	- 409,598	-	-	-	14,660 -	- (409,598)	-	14,660 -
Unit issuance – settlement of note payable (Notes 8 and 10b) Unit issuance – to be returned to	600,000	306,000	146,231	-	-	-	-	-	452,231
treasury (Notes 9 and 10b) Share issuance – warrant exercise	257,950	-	-	-	-	-	-	-	-
(Note 10b) Share issuance – option exercise	100,000	50,000	-	-	-	-	-	-	50,000
(Note 10b) Net loss (Note 16)	990,000	297,000	-	-	-	-	-	- (966,922)	297,000 (966,922)
December 31, 2017 (Restated)	44,147,283	7,796,040	1,181,804	2,664,963	4,498,512	28,450	-	(16,400,605)	(230,836)

(The accompanying notes are an integral part of these condensed consolidated interim financial statements)

Condensed Consolidated Interim Statements of Cash Flows – Amended and Restated (Unaudited)

(Expressed in Canadian dollars)

	_ ·	December 31, 2016
	\$	\$
	(Restated)	
.	(Note 16)	
Cash provided by (used in):		
Operating activities		
Net loss for the period	(966,922)	(415,584)
Adjustments for non-cash items		
Accrued interest on note payable	329	-
Amortization	18,201	9,498
Loss on settlement of debt	331,902	·
Changes in non-cash operating working capital:	,	
Other receivables and prepaid	(57,751)	27,975
Accounts payable and accrued liabilities	218,576	(51,862)
Due to related parties	63,670	48,914
	(391,995)	(381,059)
Investing activities		
Additions to equipment of property	-	(9,684)
Investment in joint venture	-	(134,988)
	-	(144,672)
Financing activities		
Proceeds from note payable	-	100,000
Proceeds from related party note	71,562	470,000
Warrants exercised	50,000	27,000
Options exercised	297,000	-
Bank indebtedness	(5,096)	-
	413,466	597,000
Effect of foreign currency on cash	13,404	1,469
Increase in cash	34,875	72,738
Cash, beginning of period	19,475	207,239
Cash, end of period	54,350	279,977
Supplemental information		
Supplemental information Interest paid		
Taxes paid	-	-
i axes paiu		<u> </u>

Supplemental disclosure with respect to cash flows (Note 14)

Notes to the Condensed Consolidated Interim Financial Statements – Amended and Restated (Unaudited)

For the three months ended December 31, 2017

(Expressed in Canadian dollars)

1. Nature of Operations and Going Concern

Mag One Products Inc. (the "Company" or "Mag One") was incorporated on June 18, 2007 in British Columbia, Canada and had its name changed to Mag One Products Inc. on March 18, 2015. The Company's head office is located at Suite 145 – 925 Georgia Street West, Vancouver, V6C 3L2. The Company's shares are traded on the Canadian Securities Exchange ("CSE").

The Company's principal business is the development and commercialization of technologies for the processing and production of magnesium metal and -related compounds and by-products and co-products from serpentinite tailings.

Going concern

These amended and restated condensed consolidated interim financial statements have been prepared on the going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. Should the Company be unable to continue as a going concern, it may be unable to realize the carrying value of its assets and to meet its liabilities as they become due. As at December 31, 2017, the Company is not able to finance its day to day activities through operations. The Company's continuation as a going concern is dependent upon its ability to attain profitable operations and generate funds there from and/or raise equity capital or borrowings sufficient to meet current and future obligations. These factors indicate the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern. Management intends to finance operating costs over the next twelve months through the issuance of its common and preferred shares. Should the Company be unable to continue as a going concern, the net realizable value of its assets may be materially less than the amounts on its consolidated statement of financial position.

2. Statement of Compliance

These amended and restated consolidated interim financial statements, including comparatives, have been prepared in accordance with International Accounting Standards ("IAS") 34, "Interim Financial Reporting" using accounting policies consistent with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and Interpretations issued by the International Financial Reporting Interpretations Committee ("IFRIC").

Accordingly, certain disclosures required in annual financial statements have been condensed or omitted. These amended and restated condensed interim financial statements are intended to provide users with an update in relation to events and transactions that are significant to an understanding of the changes in financial position and performance of the Company since the end of the last annual reporting period. It is therefore recommended that these condensed interim financial statements be read in conjunction with the most recent audited annual financial statements of the Company for the year ended September 30, 2017.

These amended and restated condensed consolidated interim financial statements were approved and authorized by the Board of Directors on August •, 2018.

Notes to the Condensed Consolidated Interim Financial Statements – Amended and Restated (Unaudited)

For the three months ended December 31, 2017

(Expressed in Canadian dollars)

3. Significant Accounting Policies

(a) Basis of Preparation

These amended and restated consolidated financial statements have been prepared on an accrual basis and are based on historical costs, except for certain financial instruments measured at their fair value, and are presented in Canadian dollars, unless otherwise noted.

The Company has not adopted new accounting policies since it recent year ended September 30, 2017.

These consolidated financial statements incorporate the accounts of the Company and the following controlled subsidiaries:

	Ownership Percentage			
Name	Country of incorporation/ formation	December 31, 2017	September 30, 2017	
Mag One Operations Inc. Mag One Operations Inc. ("Mag One	Canada	100%	100%	
USA") North American Magnesium Company	USA	100%	100%	
LLC ("NAMP LLC")	USA	100%	100%	

Inter-company balances and transactions, including unrealized income and expenses arising from inter-company transactions, are eliminated on consolidation.

Restated and amended financial statements

These condensed consolidated financial statements have been amended to correct for errors in the original financial statements. The amendments relate to corrections to the misclassification of certain amounts recorded to due from/to related parties, accounts payable and accrued liabilities, notes payable to related parties, note payable, share capital subscriptions received in advance, reserves, and subscription receivable as at December 31, 2017. An adjustment was made to gain/(loss) on settlement of debt that was incorrectly calculated. Refer to Note 16 for the detail of the restatement adjustments.

Certain prior period amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations. Refer to Note 16 for the detail of the reclassification adjustments.

(b) Accounting Standards Issued by Not Yet Adopted

IFRS 9, Financial Instruments — The IASB intends to replace IAS 39, Financial Instruments: Recognition and Measurement in its entirety with IFRS 9 which is intended to reduce the complexity in the classification and measurement of financial instruments. In February 2014, the IASB tentatively determined that the revised effective date for IFRS 9 would be January 1, 2018. The Company does not expect any significant impact from the adoption of IFRS 15.

Notes to the Condensed Consolidated Interim Financial Statements – Amended and Restated (Unaudited)

For the three months ended December 31, 2017

(Expressed in Canadian dollars)

3. Significant Accounting Policies (cont'd)

IFRS 15, Revenue from Contracts with Customers. This new standard contains a single model that applies to contracts with customers and two approaches to recognizing revenue: at a point in time or over time. The model features a contract-based five-step analysis of transactions to determine whether, how much and when revenue is recognized. New estimates and judgmental thresholds have been introduced, which may affect the amount and/or timing of revenue recognized. IFRS 15 is effective for annual periods beginning on or after January 1, 2018 with early adoption permitted. The Company does not expect any significant impact from the adoption of IFRS 15.

IFRS 16, Leases. IFRS 16 establishes principles for the recognition, measurement, presentation and disclosure of leases, with the objective of ensuring that lessees and lessors provide relevant information that faithfully represents those transactions. IFRS 16 substantially carries forward the lessor accounting requirements in IAS 17. Accordingly, a lessor continues to classify its leases as operating leases or finance leases, and to account for those two types of leases differently. However, lessees are no longer classifying leases as either operating leases or finance leases as it is required by IAS 17. The standard is effective for annual periods beginning on or after January 1, 2019. The Company has not yet evaluated the impact of this standard on the Company's consolidated financial statements.

4. Intangible assets

On May 19, 2017, the Company entered into a purchase agreement with Dundee Sustainable Technologies Inc. ("DST") to purchase a Technical Report titled "Resource Estimation of the Nickel Content in Asbestos Mines Tailings, Thetford Mines, Quebec, Canada" prepared by Systémes Geostat International (the "Technical Report") The terms of the agreement are:

- Payment of \$5,000 in cash and 40,000 common shares of the Company upon signing;
- \$20,000 in cash and \$30,000 worth of common stock in the Company at the prevailing 20day volume weighted average price upon the commencement of commercial production of product(s) by processing the Tailings if occurring within twenty four months of signing; and
- If the Company does not commence commercial production of product(s) by processing the Tailings within twenty four months of signing, the Company is required to sell back the Technical Report for consideration of \$1.00 to DST

During the year ended September 30, 2017, \$5,000 in cash was paid to DST and 40,000 common shares were issued with a fair value of \$9,000.

In connection with the SPA the Company entered into an Option Agreement ("OA") with ACL. The terms of the OA include:

- The Option to purchase up to 60,000,000 tonnes of the Tailings as identified in the Technical Report for a term of six months from signing, for consideration of 50,000 shares of the Company as a non-refundable deposit; and
- Upon exercise of the Option, the Company would be required to pay \$100,000 in cash, \$1.00/tonne of Tailings used as a royalty, and would have access to a minimum of five acres of the land for necessary plant and equipment.

Notes to the Condensed Consolidated Interim Financial Statements – Amended and Restated (Unaudited)

For the three months ended December 31, 2017

(Expressed in Canadian dollars)

4. Intangible assets (cont'd)

During the year ended September 30, 2017, \$5,000 in cash was paid to ACL and 50,000 common shares were issued with a fair value of \$11,250.

Subsequent to the period, the option was extended for an additional eight months expiring on July 19, 2018.

During the three months ended December 31, 2017, the Company recorded amortization of \$3,781 related to these intangible assets.

5. Plant and Equipment

	Laboratory \$	Equipment \$	Total \$
Cost:			
September 30, 2016	149,084	71,024	220,108
Additions	-	152,368	152,368
Transfer from construction in progress	26,234	-	26,234
Foreign currency translation	(1,771)	(2,412)	(4,183)
September 30, 2017	173,547	220,980	394,527
Foreign currency translation	1,946	(386)	1,560
December 31, 2017	175,493	220,594	396,087
Accumulated Amortization:			
September 30, 2016	22,363	3,551	25,914
Amortization	44,430	18,673	63,103
Foreign currency translation	3,320	327	3,647
September 30, 2017	70,113	22,551	92,664
Amortization	8,890	5,530	14,420
Foreign currency translation	250	54	304
December 31, 2017	79,253	28,135	107,388
Net book value:			
September 30, 2017	103,434	198,429	301,863
December 31, 2017	96,240	192,459	288,699

6. Accounts Payable and Accrued Liabilities

	December 31, 2017 \$	September 30, 2017 \$
Trade payables	414,775	208,204
Accrued liabilities	18,269	6,264
	433,044	214,468

7. Advance from Investissement Quebec

As at December 31, 2017, the Company has received \$148,500 as an advance payment in connection with \$495,000 in government funding approved for the Company by Investissement Quebec. The terms of the funding approved allow for 44.09% of qualified expenditures being eligible for a non-refundable reimbursement by Investissement Quebec.

Notes to the Condensed Consolidated Interim Financial Statements – Amended and Restated (Unaudited)

For the three months ended December 31, 2017

(Expressed in Canadian dollars)

The Company is in the process of submitting a claim to obtain formal non-refundable status for the \$148,500 advanced to date.

8. Notes Payable

During the year ended September 30, 2016, the Company entered into a promissory note with an arm-length party whereby the Company can borrow up to \$100,000. The note is unsecured, due on demand, and bears interest at 10% per annum. During the year ended September 30, 2017, the Company received loan proceeds of \$50,000 (2016 - \$50,000). As of September 30, 2017, the Company has a balance payable including principal and accrued interest of \$120,000 (2016 - \$50,000). \$7,150 in finder's fees were charged on the note. On October 5, 2017, this promissory note was repaid in full with issuance of 600,000 units of the Company (Notes 10 and 14). Each share purchase warrant can be exercised into one common share at \$0.50 per share for two years following the issuance date. The fair value of the debt settlement was estimated at \$452,231 and the Company recorded a loss on settlement of the debt of \$331,902.

9. Related Party Transactions

Compensation paid to key management and directors

The following are the remuneration of the Company's related parties:

Three months ended December 31,	2017 \$	2016 \$
Chairman of the Board (the "Chairman") Company of the president and the Chief	24,000	24,000
Executive Officer ("CEO") of a subsidiary	36,000	24,000
Company of the Chairman	15,000	-
	75,000	48,000

Amounts due to related parties

	December 31, 2017 \$	September 30, 2017 \$
Company of the President and the CEO of a subsidiary	71,746	42,076
Chairman	71,386	186,750
Family member of key management	34,176	-
	177,308	228,826

Except for the notes payable to related parties below, all amounts owing to related parties do not bear any interest, are unsecured and are due on demand.

Notes to the Condensed Consolidated Interim Financial Statements – Amended and Restated (Unaudited)

For the three months ended December 31, 2017

(Expressed in Canadian dollars)

9. Related Party Transactions (cont'd)

Notes payable to related parties

During the year ended September 30, 2016, the Company issued a promissory note of \$50,000 payable to a company controlled by the former CEO (the "Promissory Note A"). This note was unsecured, due on demand, and bears interest at 5% per annum. As at September 30, 2017, the Company has a balance payable of \$nil (2016 - \$53,750) including principal and accrued interest.

During the year ended September 30, 2017, the Company issued a promissory note of \$400,000 payable to the spouse of the Company's former CEO (the "Promissory Note B"). The note was secured by a corporate guarantee provided by the Company and a personal guarantee from a director of the Company, due on March 19, 2017 and bears interest of 10% per annum.

During the year ended September 30, 2017, the Promissory Notes A and B including principals and accrued interest were repaid in full as follows.

- A cash payment of \$250,000;
- A cash payment of \$150,000 paid by the Chairman on behalf of the Company during the year ended September 30, 2017.
- 100,000 common shares of the Company with the fair value of \$21,500. The Company recorded a gain on settlement of the loans of \$60,120.

Other transactions

During the three months ended December 31, 2017, the Company received \$37,386 and \$34,176 from the Chairman and a family member related to the Chairman, respectively for short term working capital needs. The advances bear no interest, are unsecured and are payable on demand.

On October 5, 2017 the Company issued 125,000 units of the Company to a family member of a director in relation to the \$25,000 subscriptions received in advance during the year ended September 30, 2017 (Note 10). Each share purchase warrant can be exercised into one common share at \$0.50 per share for two years following the issuance date.

On October 5, 2017 the Company issued 1,002,930 units to the Chairman in relation to the \$200,586 subscriptions received in advance during the year ended September 30, 2017 (Note 10). Each share purchase warrant can be exercised into one common share at \$0.50 per share for two years following the issuance date.

On October 5, 2017 the Company issued 20,060 units of the Company to a family member of the chairman in relation to the \$4,012 subscriptions received in advance during the year ended September 30, 2017 (Note 10). Each share purchase warrant can be exercised into one common share at \$0.50 per share for two years following the issuance date.

On October 5, 2017, the Company issued 257,950 units of the Company in error. Each unit consists of one common share and one share purchase warrant. Subsequent to issuance, these units will be returned to treasury of the Company for cancellation.

Notes to the Condensed Consolidated Interim Financial Statements – Amended and Restated (Unaudited)

For the three months ended December 31, 2017

(Expressed in Canadian dollars)

9. Related Party Transactions (cont'd)

On October 27, 2017, a company controlled by the CEO exercised 400,000 options with an exercise price of \$0.30 for total proceeds of \$120,000 (Note 10).

On October 27, 2017, the CEO of the Company exercised 100,000 warrants with an exercise price of \$0.50 for total proceeds of \$50,000 (Note 10).

On November 23, 2017, a company controlled by the CEO exercised 200,000 options with an exercise price of \$0.30 for total proceeds of \$60,000 (Note 10).

On November 23, 2017, a director of the Company exercised 80,000 options with an exercise price of \$0.30 for total proceeds of \$24,000 (Note 10).

On November 30, 2017, a company controlled by the CEO exercised 100,000 options with an exercise price of \$0.30 for total proceeds of \$30,000 (Note 10).

On November 30, 2017, the CEO of the Company exercised 40,000 options with an exercise price of \$0.30 for total proceeds of \$12,000 (Note 10).

On December 6, 2017, the CEO of the Company exercised 100,000 options with an exercise price of \$0.30 for total proceeds of \$30,000 (Note 10).

On December 21, 2017, the CEO of the Company exercised 70,000 options with an exercise price of \$0.30 for total proceeds of \$21,000 (Note 10).

During the year ended September 30, 2017, the Company issued 300,000 units of the Company to a family member of the Chairman at a price of \$0.70 per unit for gross proceeds of \$210,000.

During the year ended September 30, 2017, the Company issued 500,000 units of the Company to a company controlled by the Chairman at a price of \$0.20 per unit for gross proceeds of \$100,000.

During the year ended September 30, 2017, the Company settled a balance of \$30,700 payable to the Chairman with the issuance of 153,500 units of the Company. The fair value of the debt settlement was estimated at \$64,623 and the Company recorded a loss on settlement of the debt of \$33,923.

During the year ended September 30, 2017, the Company issued 446,500 units to the Chairman in error. These units will be returned to treasury for cancellation.

10. Share Capital

(a) Authorized

Unlimited number of Class A common shares without par value. Unlimited number of non-voting Class B preferred without par value.

Notes to the Condensed Consolidated Interim Financial Statements – Amended and Restated (Unaudited)

For the three months ended December 31, 2017

(Expressed in Canadian dollars)

10. Share Capital (cont'd)

(b) Common shares - Issued and outstanding

During the three months ended December 31, 2017, the Company issued:

On October 5, 2017, the Company issued 600,000 units of the Company in full settlement of a note payable of \$120,000 (Notes 8 and 14). Each unit consists of one common share and one share purchase warrant. Each share purchase warrant can be exercised into one common share at \$0.50 per share for two years following the issuance date. The fair value of the debt settlement was estimated at \$452,231, including the shares valued at \$306,000 and the warrants estimated at \$146,231. The warrants were measured using the Black Scholes option pricing model with the following assumptions and inputs: expected life 2 years; volatility 131%; dividend yield 0%; and risk free rate 1.55%.

On October 5, 2017 the Company issued 125,000 units of the Company to a family member of a director in relation to the subscriptions received in advance (Note 9). Each unit consists of one common share and one share purchase warrant. Each share purchase warrant can be exercised into one common share at \$0.50 per share for two years following the issuance date.

On October 5, 2017 the Company issued 1,002,930 units to the Chairman in relation to subscriptions received in advance (Note 9). Each unit consists of one common share and one share purchase warrant. Each share purchase warrant can be exercised into one common share at \$0.50 per share for two years following the issuance date.

On October 5, 2017 the Company issued 20,060 units of the Company to a family member of the chairman in relation to the subscriptions received in advance (Note 9). Each unit consists of one common share and one share purchase warrant. Each share purchase warrant can be exercised into one common share at \$0.50 per share for two years following the issuance date.

On October 5, 2017, the Company issued 257,950 units of the Company in error. Each unit consists of one common share and one share purchase warrant. Subsequent to issuance, these units will be returned to treasury of the Company for cancellation.

On October 5, 2017 an additional 900,000 units were issued to non-related parties in relation to the subscriptions received in advance. Each unit consists of one common share and one share purchase warrant. Each share purchase warrant can be exercised into one common share at \$0.50 per share for two years following the issuance date.

On October 27, 2017, a company controlled by the CEO exercised 400,000 options with an exercise price of \$0.30 for total proceeds of \$120,000 (Note 9).

Notes to the Condensed Consolidated Interim Financial Statements – Amended and Restated (Unaudited)

For the three months ended December 31, 2017

(Expressed in Canadian dollars)

10. Share Capital (cont'd)

(b) Common shares - Issued and outstanding (cont'd)

On October 27, 2017, the CEO of the Company exercised 100,000 warrants with an exercise price of \$0.50 for total proceeds of \$50,000 (Note 9).

On November 23, 2017, a company controlled by the CEO exercised 200,000 options with an exercise price of \$0.30 for total proceeds of \$60,000 (Note 9).

On November 23, 2017, a director of the Company exercised 80,000 options with an exercise price of \$0.30 for total proceeds of \$24,000 (Note 9).

On November 30, 2017, a company controlled by the CEO exercised 100,000 options with an exercise price of \$0.30 for total proceeds of \$30,000 (Note 9).

On November 30, 2017, the CEO of the Company exercised 40,000 options with an exercise price of \$0.30 for total proceeds of \$12,000 (Note 9).

On December 6, 2017, the CEO of the Company exercised 100,000 options with an exercise price of \$0.30 for total proceeds of \$30,000 (Note 9).

On December 21, 2017, the CEO of the Company exercised 70,000 options with an exercise price of \$0.30 for total proceeds of \$21,000 (Note 9).

Warrants

	Three months ended December 31, 2017			Year ended September 30, 2017		
	Warrants	Weighted Average Exercise Price		Warrants	Ave Exe	ighted erage ercise rice
Opening	6,143,560	\$	0.64	2,958,611	\$	0.95
Granted	2,905,940		0.50	5,181,060		0.55
Exercised	(100,000)		0.50	(95,000)		0.60
Expired			-	(1,901,111)		0.89
Ending	8,949,500	\$	0.60	6,143,560	\$	0.64

As at December 31, 2017, the Company had the following warrants outstanding:

Number	Exercise price	Expiry date
412,500	\$1.10	August 26, 2020
550,000	\$1.10	August 16, 2018
312,000	\$1.40	March 9, 2018
4,769,060	\$0.50	August 17, 2019
2,905,940	\$0.50	October 10, 2019
8,949,500		

As at December 31, 2017, warrants outstanding have an average life of 1.61 years and average exercise price of \$0.60.

Notes to the Condensed Consolidated Interim Financial Statements – Amended and Restated (Unaudited)

For the three months ended December 31, 2017

(Expressed in Canadian dollars)

10. Share Capital (cont'd)

Options

On September 14, 2017, the Company granted a total of 4,000,000 stock options to certain officers, directors and/or consultants of the Company exercisable at \$0.30 for a period of two years. The fair value of the stock options was determined to be \$756,992 calculated using the Black-Scholes Option Pricing Model with the following assumptions: expected life of options -2 years; expected volatility -125%; expected dividend yield -0%; and risk-free rate -1.58%.

As at December 31, 2017, 3,010,000 stock options remain outstanding.

11. Financial Instruments

(a) Classification of Financial Instruments

The Company has classified its financial instruments as follows:

	December 31, 2017 \$	September 30, 2017 \$
	(Restated)	(Restated)
Financial assets:		
Loans and receivables:		
Cash	54,350	19,475
	54,350	19,475
Financial liabilities		
Cheques in excess of funds available	-	5,096
Accounts payable	414,775	208,204
Due to related parties	177,308	42,076
Notes payable	<u> </u>	120,000
	592,083	375,376

(b) Fair Values

The Company has classified fair value measurements of its financial instruments using a fair value hierarchy that reflects the significance of inputs used in making the measurements as follows:

- Level 1: Valuation based on quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2: Valuations based on directly or indirectly observable inputs in active markets for similar assets or liabilities, other than Level 1 prices, such as quoted interest or currency exchange rates; and
- Level 3: Valuations based on significant inputs that are not derived from observable market data, such as discounted cash flow methodologies based on internal cash flow forecasts.

Notes to the Condensed Consolidated Interim Financial Statements – Amended and Restated (Unaudited)

For the three months ended December 31, 2017

(Expressed in Canadian dollars)

11. Financial Instruments (cont'd)

The Company does not have any Level 2 or 3 fair value measurements.

As at December 31, 2017, the fair values of the Company's financial instruments approximate their carrying values due to the relatively short-term maturity of these instruments.

(c) Credit Risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The Company's primary exposure to credit risk is on its cash which is held in bank accounts. As most of the Company's cash is held by two banks, there is a concentration of credit risk. This risk is low, and is managed by using major banks that are high credit quality financial institutions as determined by rating agencies. The maximum exposure to credit risk is the carrying amount of the Company's financial instruments. The Company's secondary exposure to credit risk is on its receivables. This risk is minimal as receivables consists primarily of refundable government goods and services taxes.

(d) Foreign currency exchange rate risk

Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency. The Company is not exposed to foreign exchange risk.

(e) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's exposure to interest rate risk is minimal.

(f) Liquidity Risk

Liquidity risk is the risk that the Company may be unable to meet its financial obligations as they fall due. The Company reviews its working capital position regularly to ensure there is sufficient capital in order to meet short-term business requirements, taking into account its anticipated cash flows from operations and its holdings of cash.

12. Capital Management

The Company's policy is to maintain a strong capital base so as to maintain investor and creditor confidence, safeguard the Company's ability to support the development of its projects and to sustain future development of the business. The capital structure of the Company consists of working and share capital. There are no restrictions on the Company's capital. There were no changes in the Company's approach to capital management during the period.

Notes to the Condensed Consolidated Interim Financial Statements – Amended and Restated (Unaudited)

For the three months ended December 31, 2017

(Expressed in Canadian dollars)

13. Commitments

a) During the year ended September 30, 2015, the Company, through its wholly-owned subsidiary MagOne USA, entered into a definitive agreement to acquire 100% of North American Magnesium Products, LLC ("NAMP LLC"), a LLC formed by Orion Laboratories, LLC.

The members of Orion Laboratories LLC will receive up to 40,000,000 common shares of the Company based on the operating performance of the Company at one common share for \$1.00 operating profit of the Company earned.

- b) On August 31, 2017 the Company entered into an agreement to purchase 100% of the shares of MagPower Systems Inc. ('MagPower"). MagPower is a private company whose focus is the development of magnesium air batteries. The terms of the acquisition include:
 - \$100 for all of the issued and outstanding shares;
 - 2% royalty ("royalty obligation") based on gross cash flow generated by MagPower up to \$2 million;
 - An option for the Company to buy the royalty obligation for \$1 million for a period of 24 months; and
 - Warrants issued on a prorata basis to existing MagPower shareholders with a term of two years, at a price of \$1.00 for the first year, and \$1.25 for the second year.

As at December 31, 2017, the acquisition has not been finalized, no consideration has been paid, and ownership had not been transferred.

14. Supplemental disclosure with respect to cash flows

Significant non-cash transactions for the three months ended December 31, 2017 are as follows:

On October 5, 2017, the Company issued 600,000 units of the Company in full settlement of a note payable of \$120,000 (Notes 8 and 10).

During the three months ended December 31, 2016, the Company did not incur any significant non-cash transactions.

Notes to the Condensed Consolidated Interim Financial Statements – Amended and Restated (Unaudited)

For the three months ended December 31, 2017

(Expressed in Canadian dollars)

15. Subsequent Events

On January 11, 2018, the Company received \$256,467 from IQ in connection with a reimbursement of eligible expenditures incurred on its Phase 1 Pilot Plant.

On January 22, 2018, the Company extended its option to purchase up to 60,000,000 tonnes of Tailings from ACL by eight months, expiring July 19, 2018.

On February 23, 2018, the Company received an additional \$90,033 from IQ in connection with a reimbursement of eligible expenditures incurred on its Phase 1 Pilot Plant.

On April 4, 2018, the CEO of the Company subscribed to 250,000 units at \$0.20 per unit for total proceeds of \$50,000. Each unit consists of one common share and one share purchase warrant. Each share purchase warrant can be exercised into one common share at \$0.50 per share for one year following the issuance date. As of the date of these financial statements, these units have not been issued.

On April 4, 2018 the Company entered into a loan agreement with the CEO of the Company for working capital purposes in the amount of \$50,000. The loan payable is unsecured, due on demand and non-interest bearing.

On April 13, 2018, the Company issued a convertible debenture in the amount of \$50,000. The debenture bears interest at 6% per annum, with interest of \$3,000 paid in advance, matures on March 31, 2021, and is secured by the Company's assets. The debenture is convertible into common shares of the Company after April 30, 2019 at the lower of \$0.50 per share or the average 10-day trading price at time of notice.

On May 7, 2018, the Company issued a convertible debenture in the amount \$100,000. The debenture bears interest at 8% per annum, with interest of \$8,000 paid in advance, matures on March 31, 2021, and is secured by the Company's assets. The debenture is convertible into common shares of the Company after April 30, 2019 at the lower of \$0.50 per share or the average 10-day trading price at time of notice.

16. Restatement of Consolidated Financial Statements

The unaudited condensed consolidated financial statements of the Company as at December 31, 2017 and for the three months then ended have been restated to reflect the restatement of the annual consolidated financial statements as at September 30, 2017 and for the year then ended, as well as to correct material errors and omissions in its prior filing. The Company discovered the deficiencies in the accounting information subsequent to the filing and issuance of the financial statements and now wishes to rectify the situation by restating the financial statements for the period ended December 31, 2017 using the updated and complete information currently available.

Notes to the Condensed Consolidated Interim Financial Statements – Amended and Restated (Unaudited)

For the three months ended December 31, 2017

(Expressed in Canadian dollars)

16. Restatement of Consolidated Financial Statements (cont'd)

The effects of the restatement are as follows:

Statement of Financial Position as at September 30, 2017

	September 30, 2017		September 30, 2017
	(Original)	Adjustments	(Restated)
	\$	\$	\$
Assets			
Current Assets			
Cash	19,475	-	19,475
Sales tax receivable	100,747	-	100,747
Due from related parties	56,000	(56,000)	-
	176,222	(56,000)	120,222
Property and equipment	301,863	_	301,863
Intangible asset	30,250	-	30,250
	508,335	(56,000)	452,335
Liabilities and Shareholders' Equity		· · · · · ·	
Current Liabilities			
Cheques in excess of funds available	5,096	-	5,096
Accounts payable and accrued liabilities	334,468	(120,000)	214,468
Advance	148,500	-	148,500
Due to related parties	206,826	(164,750)	42,076
Note payable to related party	100,000	(100,000)	-
Note payable	-	120,000	120,000
	794,890	(264,750)	530,140
Shareholders' Equity			
Share capital	6,807,392	(73,950)	6,733,442
Reserves	8,194,265	18,573	8,212,838
Subscriptions received in advance	581,188	(171,590)	
Subscriptions receivable	(291,527)	291,527	
Deficit	(15,577,873)	144,190	(15,433,683)
	(286,555)	208,750	(77,805)
	508,335	(56,000)	452,335

Notes to the Condensed Consolidated Interim Financial Statements – Amended and Restated (Unaudited)

For the three months ended December 31, 2017

(Expressed in Canadian dollars)

Statement of Financial Position as at December 31, 2017

	December 31, 2017		December 31, 2017
	(Original) \$	Adjustments \$	(Restated) \$
Assets			
Current Assets			
Cash Sales tax receivable Due from related parties	48,594 140,935 2,923	5,756 600 14,040	54,350 141,535 16,963
	192,450	20,396	212,848
Property and equipment Intangible asset	234,847 24,438	53,852 2,031	288,699 26,469
	451,737	76,279	528,016
Liabilities and Shareholders' Equity			
Current Liabilities			
Accounts payable and accrued liabilities Advance from Investissement Québec Due to related parties Note payable	570,694 148,500 188,338 100,000	(137,650) - (11,030) (100,000)	433,044 148,500 177,308
	1,007,532	(248,680)	758,852
Shareholders' Equity		,	
Share capital Reserves Subscriptions received in advance (receivable) Deficit	7,735,580 8,215,151 (231,965) (16,274,561)	60,460 158,578 231,965 (126,044)	7,796,040 8,373,729 - (16,400,605)
255	(555,795)	324,959	(230,836)
	451,737	76,279	528,016

Notes to the Condensed Consolidated Interim Financial Statements – Amended and Restated (Unaudited)

For the three months ended December 31, 2017

(Expressed in Canadian dollars)

16. Restatement of Consolidated Financial Statements (cont'd)

Statement of Loss and Comprehensive Loss

	Three months ended December 31, 2017		Three months ended December 31, 2017
	(Original) \$	Adjustments \$	(Restated)
Administrative Expenses			
Amortization	74,637	(56,436)	18,201
Office and administration	21,455	9,992	31,447
Professional and consulting fees	165,375	(14,040)	151,335
Investor communication	140,500	` '	140,499
Research	255,398		255,398
Travel	33,483		33,483
Trust and filing fees	4,260	-	4,260
	(695,108)	60,485	(634,623)
Other Item			
Interest expense	(1,580)		(397)
Gain on settlement of debt	-	(331,902)	(331,902)
Net loss for the period	(696,688)	(270,234)	(966,922)
Other comprehensive income			
Foreign currency translation adjustment	20,886	(6,226)	14,660
Comprehensive loss for the period	(675,802)	(276,460)	(952,262)

Notes to the Condensed Consolidated Interim Financial Statements – Amended and Restated (Unaudited)

For the three months ended December 31, 2017

(Expressed in Canadian dollars)

16. Restatement of Consolidated Financial Statements (cont'd)

Statement of Cash Flows

	Three months ended December		Three months ended December
	31, 2017 (Original) \$	Adjustments	31, 2017
Cash provided by (used in):			
Operating activities			
Net loss for the period	(696,688)	(270,234)	(966,922)
Adjustments for non-cash items Accrued interest on note payable	1,512	(1,183)	329
Amortization	74,637	, ,	
Gain on settlement of debt Changes in non-cash operating working capital:	-	331,902	
Other receivables and prepaid	(43,111)	,	, ,
Accounts payable and accrued liabilities	236,226	, ,	218,576
Due to related parties	36,000	<u> </u>	63,670
Financina activities	(391,424)	(571)	(391,995)
Financing activities Proceeds from related party note	_	71,562	71,562
Warrants exercised	50,000	•	50,000
Options exercised	297,000		297,000
Subscriptions received	59,562		, -
Bank indebtedness	(5,096)	-	(5,096)
	401,466	12,000	413,466
Effect of foreign currency on cash	19,077	(5,673)	13,404
Increase in cash	29,119	•	34,875
Cash, beginning of period	19,475	-	19,475
Cash, end of period	48,594	5,756	54,350